Cadrenal Therapeutics, Inc. (CVKD) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cadrenal Therapeutics, Inc. on September 5, 2024. The Company is a Delaware corporation with its principal executive offices in Ponte Vedra, Florida, and its common stock trades on the Nasdaq Capital Market under the symbol "CVKD". The report addresses a specific regulatory matter regarding the Company's continued listing status.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a listing compliance notification and does not contain financial statements or operational financial data.
Material Changes
The primary material event reported is the resolution of a listing deficiency. The Company received a Notification Letter from The Nasdaq Stock Market confirming that the closing bid price of its common stock was at or above $1.00 per share for the last 10 consecutive business days (August 20, 2024, through September 4, 2024). Consequently, the Company has regained compliance with Listing Rule 5550(a)(2), and the matter is now closed.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, or discussion of risks and contingencies beyond the resolution of the specific listing issue. No unusual items were reported in this document.
Key Facts for Investor Verification
- The Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) regarding minimum bid price requirements.
- The compliance period was verified from August 20, 2024, to September 4, 2024.
- The filing does not include updated financial performance data; investors should refer to the most recent 10-Q or 10-K for financial metrics.
- The Company is classified as an emerging growth company.